Eurofins Scientific SE, through its subsidiaries, provides various analytical testing services worldwide.
Reasonable growth potential with adequate balance sheet.
Share Price & News
How has Eurofins Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ERF has not had significant price volatility in the past 3 months.
7 Day Return
FR Life Sciences
1 Year Return
FR Life Sciences
Return vs Industry: ERF underperformed the French Life Sciences industry which returned 23.5% over the past year.
Return vs Market: ERF exceeded the French Market which returned -21.8% over the past year.
Price Volatility Vs. Market
How volatile is Eurofins Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StWhat Does Eurofins Scientific SE's (EPA:ERF) P/E Ratio Tell You?
3 weeks ago | Simply Wall StCan You Imagine How Eurofins Scientific's (EPA:ERF) Shareholders Feel About The 62% Share Price Increase?
1 month ago | Simply Wall StWhat Type Of Shareholder Owns Eurofins Scientific SE's (EPA:ERF)?
Is Eurofins Scientific undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ERF (€440) is trading below our estimate of fair value (€632.89)
Significantly Below Fair Value: ERF is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ERF is poor value based on its PE Ratio (53.8x) compared to the Life Sciences industry average (49.9x).
PE vs Market: ERF is poor value based on its PE Ratio (53.8x) compared to the French market (13.2x).
Price to Earnings Growth Ratio
PEG Ratio: ERF is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: ERF is good value based on its PB Ratio (2.8x) compared to the XE Life Sciences industry average (4.1x).
How is Eurofins Scientific forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ERF's forecast earnings growth (26.4% per year) is above the savings rate (-0.1%).
Earnings vs Market: ERF's earnings (26.4% per year) are forecast to grow faster than the French market (12% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ERF's revenue (5.9% per year) is forecast to grow faster than the French market (3.5% per year).
High Growth Revenue: ERF's revenue (5.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ERF's Return on Equity is forecast to be low in 3 years time (14.1%).
How has Eurofins Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ERF has a large one-off loss of €90.8M impacting its December 31 2019 financial results.
Growing Profit Margin: ERF's current net profit margins (3.2%) are lower than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: ERF's earnings have grown by 17.9% per year over the past 5 years.
Accelerating Growth: ERF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ERF had negative earnings growth (-17%) over the past year, making it difficult to compare to the Life Sciences industry average (6.3%).
Return on Equity
High ROE: ERF's Return on Equity (6.7%) is considered low.
How is Eurofins Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: ERF's short term assets (€1.6B) exceed its short term liabilities (€1.6B).
Long Term Liabilities: ERF's short term assets (€1.6B) do not cover its long term liabilities (€3.3B).
Debt to Equity History and Analysis
Debt Level: ERF's debt to equity ratio (102.6%) is considered high.
Reducing Debt: ERF's debt to equity ratio has reduced from 107.3% to 102.6% over the past 5 years.
Debt Coverage: ERF's debt is well covered by operating cash flow (22.8%).
Interest Coverage: ERF's interest payments on its debt are well covered by EBIT (4.7x coverage).
Inventory Level: ERF has a high level of physical assets or inventory.
Debt Coverage by Assets: ERF's debt is not covered by short term assets (assets are 0.5x debt).
What is Eurofins Scientific's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ERF's dividend (0.78%) isn’t notable compared to the bottom 25% of dividend payers in the French market (2.07%).
High Dividend: ERF's dividend (0.78%) is low compared to the top 25% of dividend payers in the French market (6.44%).
Stability and Growth of Payments
Stable Dividend: ERF is not paying a notable dividend for the French market, therefore no need to check if payments are stable.
Growing Dividend: ERF is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ERF is not paying a notable dividend for the French market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ERF's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Gilles Martin (56yo)
Dr. Gilles G. Martin, Ph.D., serves as the Chief Executive Officer at Eurofins Scientific, Inc. Dr. Martin serves as Chief Executive Officer of Eurofins Nihon Kankyo K.K. and Eurofins Scientific Group. He ...
CEO Compensation Analysis
Compensation vs Market: Gilles's total compensation ($USD1.30M) is below average for companies of similar size in the French market ($USD2.79M).
Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.
|Chairman of the Board & CEO||no data||€1.19m||0.000010% €746.0|
|Executive Director||30.25yrs||€293.69k||0.000010% €746.0|
|Executive Director||28.25yrs||€354.00k||0.081% €6.1m|
|Independent Non-Executive Director||3yrs||€78.02k||no data|
|Independent Non-Executive Director||8.25yrs||€78.02k||0.00031% €23.1k|
|Independent Non-Executive Director||6yrs||€78.02k||no data|
Experienced Board: ERF's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Eurofins Scientific SE's company bio, employee growth, exchange listings and data sources
- Name: Eurofins Scientific SE
- Ticker: ERF
- Exchange: ENXTPA
- Founded: 1987
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: €7.460b
- Shares outstanding: 17.92m
- Website: https://www.eurofins.com
Number of Employees
- Eurofins Scientific SE
- Val Fleuri 23
- Luxembourg City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ERFS.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Nov 1997|
|ERF||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Nov 1997|
|ESF||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 1997|
|0MV5||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Nov 1997|
|ERFP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Nov 1997|
|ERF||SWX (SIX Swiss Exchange)||Yes||Ordinary Shares||CH||CHF||Nov 1997|
|ESF||ETLX (Eurotlx)||Yes||Ordinary Shares||IT||EUR||Nov 1997|
|ERRF.Y||OTCPK (Pink Sheets LLC)||UNSPONSORE ADR||US||USD||May 2017|
|ERFNV||ENXTPA (Euronext Paris)||EUR0.1 (RFD 01/01/2020)||FR||EUR||Jan 2020|
Eurofins Scientific SE, through its subsidiaries, provides various analytical testing services worldwide. The company offers a portfolio of approximately 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as for clinical diagnostic. It provides agro science, agro testing, biopharma, contract development and manufacturing organization, clinical diagnostics, consumer product testing, cosmetics testing, digital testing, electrical and electronics, environment testing, food and feed testing, forensic, genomic, industrial, materials and engineering, medical device, and REACH services. The company serves clients from a range of industries, including the pharmaceutical, food, environmental, and clinical diagnostics sectors. It operates approximately 800 laboratories in 47 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/04 00:22|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.